Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy

Stopped early · Phase 2

Conditions studied: Iron Overload Due to Repeated Red Blood Cell Transfusions

In brief

The purpose of this study is to evaluate SSP-004184AQ in patients with transfusional iron overload whose primary diagnosis is hereditary or congenital anemia. SSP-004184AQ is an iron chelator under development for chronic daily oral administration to patients with transfusional iron overload.

Key facts

Study ID: NCT01604941
Run by: Shire
People needed: 32
Starts: 2012-09-14
Expected to finish: 2014-04-18
Last updated by the study team: 2021-06-29

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Willing and able to sign the approved informed consent.
Age: 18-60 years old, inclusive, at Screening.
Subjects who have received more than 20 transfusions in their lifetime and who have transfusional iron overload requiring chronic treatment with an iron chelator. N.B.: Sickle Cell Disease subjects receiving regular exchange transfusions and iron overloaded subjects with thalassemia intermedia who are receiving regular transfusions (transfusion dependent thalassemia intermedia) are eligible.
Willing to discontinue all existing iron chelation therapies for a minimum period of one to five days prior to first dose of SSP-004184AQ, the 24 week duration of the study and 1 week after last dose for a total of approximately 26 weeks.
Willing to fast two hours prior to and one hour after each dose.
Serum ferritin >500ng/mL at Screening.
Baseline liver iron concentration is greater than or equal to 5mg iron per g (equivalent dry weight, liver)determined by FerriScan® R2 MRI.
Mean of the previous three pre-transfusion hemoglobin concentrations is greater than or equal to 7.5g/dL.
Adult female subjects should be:
Post-menopausal (12 consecutive months of spontaneous amenorrhea), or
Surgically sterile, or
Females of child-bearing potential must have a negative beta-HCG pregnancy test at the Screening Visit and a negative urine pregnancy test at the Baseline Visit.
Females of child-bearing potential must agree to abstain from sexual activity that could result in pregnancy or agree to use acceptable methods of contraception.

You may not qualify if…

As a result of medical review, physical examination, or Screening investigations, the Principal Investigator (PI) considers the subject unfit for the study.
Non-elective hospitalization within the 30 days prior to Baseline testing.
Evidence of clinically relevant oral, cardiovascular, gastrointestinal, hepatic, biliary, renal, endocrine, pulmonary, neurologic, psychiatric, immunologic, bone marrow, or skin disorder that contraindicates dosing with SSP-004184AQ.
Iron overload from causes other than transfusional siderosis.
Evidence of severe renal insufficiency, eg, serum creatinine 1.5X above the upper limit of normal or proteinuria greater than 1 gm per day or a calculated glomerular filtration rate <60mL/min.
Severe iron overload including:
T2* MRI <10 ms
liver iron concentration by FerriScan R2 MRI >30mg/g liver (dw)
Known sensitivity to magnesium stearate, croscarmellose sodium or SSP-004184AQ.
Platelet count below 100,000/μL or absolute neutrophil count less than 1500/mm3 at Screening.
Insufficient venous access that precludes prescribed blood draws for safety laboratory assessments.
ALT at Screening >200 IU/L.
Use of any investigational agent within the 30 days prior to the Baseline testing.
Pregnant or lactating females.
Cardiac left ventricular ejection fraction
Below the locally determined normal range in the 12 months prior to Screening by echocardiograph or MRI or
<50% at Baseline testing by MRI (echocardiograph is acceptable for LVEF if MRI information is not available).

Where it is running

Children's Center for Cancer and Blood Diseases — Los Angeles, California, United States
Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois, United States
Weill Cornell Medical College — New York, New York, United States
Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
Toronto General Hospital — Toronto, Ontario, Canada
Ain Shams University Pediatric Hospitals — Cairo, Egypt
Cairo University Pediatric Hospitals — Cairo, Egypt
Centro della Microcitemia e delle Anemie Congenite — Genova, Genoa, Italy
San Luigi Hospital Thalassemia Centre — Orbassano, Torino, Italy
Ospedale Regionale Microcitemie — Cagliari, Italy
Ospedale Maggiore Policlinico — Milan, Italy
American University of Beirut Medical Center — Beirut, Lebanon

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.